RemeGen Ltd.

Chinese biotechs are racing to push back the frontiers of combination therapies for antibody-drug conjugates (ADCs), progressing multiple assets into mid-stage clinical development. Beyond the validat

Less than two months after saying that it would wind down its business of stem cell-based therapies for blood cancers, Vor Bio of the US has bounced back, rebranding as an autoimmune disease company a

RemeGen’s telitacicept, the world’s first approved fusion protein targeting B-cell lymphocyte stimulator/a proliferation inducing ligand (BLyS/APRIL), is looking increasingly likely to provide a stron

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from